Sean Lee
Stock Analyst
(2.64)
# 3,338
Out of 4,648 analysts
61
Total ratings
31.75%
Success rate
0.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATEC Alphatec Holdings | Reiterates: Buy | $20 | $8.36 | +139.23% | 10 | Oct 31, 2024 | |
| VSTM Verastem | Reiterates: Buy | $7 | $3.90 | +79.49% | 11 | Oct 18, 2024 | |
| PSTV Plus Therapeutics | Reiterates: Buy | $8 | $1.36 | +488.19% | 8 | Aug 16, 2024 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $2 → $6 | $16.96 | -64.62% | 7 | Aug 14, 2024 | |
| CTSO Cytosorbents | Reiterates: Neutral | $1 | $0.87 | +14.88% | 10 | Aug 14, 2024 | |
| MYO Myomo | Maintains: Buy | $6.5 → $7.5 | $3.83 | +95.82% | 3 | Aug 12, 2024 | |
| KZIA Kazia Therapeutics | Reiterates: Buy | $20 | $6.58 | +203.95% | 4 | Jul 12, 2024 | |
| CASI CASI Pharmaceuticals | Maintains: Buy | $12 → $6 | $6.14 | -2.20% | 7 | May 15, 2024 | |
| AKTX Akari Therapeutics, | Initiates: Buy | $30 | $2.43 | +1,134.87% | 1 | Dec 5, 2022 |
Alphatec Holdings
Oct 31, 2024
Reiterates: Buy
Price Target: $20
Current: $8.36
Upside: +139.23%
Verastem
Oct 18, 2024
Reiterates: Buy
Price Target: $7
Current: $3.90
Upside: +79.49%
Plus Therapeutics
Aug 16, 2024
Reiterates: Buy
Price Target: $8
Current: $1.36
Upside: +488.19%
Monopar Therapeutics
Aug 14, 2024
Maintains: Buy
Price Target: $2 → $6
Current: $16.96
Upside: -64.62%
Cytosorbents
Aug 14, 2024
Reiterates: Neutral
Price Target: $1
Current: $0.87
Upside: +14.88%
Myomo
Aug 12, 2024
Maintains: Buy
Price Target: $6.5 → $7.5
Current: $3.83
Upside: +95.82%
Kazia Therapeutics
Jul 12, 2024
Reiterates: Buy
Price Target: $20
Current: $6.58
Upside: +203.95%
CASI Pharmaceuticals
May 15, 2024
Maintains: Buy
Price Target: $12 → $6
Current: $6.14
Upside: -2.20%
Akari Therapeutics,
Dec 5, 2022
Initiates: Buy
Price Target: $30
Current: $2.43
Upside: +1,134.87%